ISRCTN73274643已完成不适用
on-Hodgkins lymphoma T-cell protocol
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. T-cell non-Hodgkin's lymphoma
- •2. Stages I-IV
- •3. Confirmed remission achieved
- •4. Less than 25% blasts in bone marrow
- •5. No circulating blasts in blood
- •6. Aged <18 years
排除标准
- •Patients with T-cell anaplastic lymphoma or peripheral T-cell lymphoma are excluded.
研究者
相似试验
招募中
1 期
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)Non-Hodgkin LymphomaAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01853631Baylor College of Medicine64
已完成
不适用
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyNon-Hodgkin T-cell LymphomaNCT02691351Samsung Medical Center500
进行中（未招募）
1 期
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)Non-Hodgkin's LymphomaB-Cell ALLB-Cell CLLNCT02050347Baylor College of Medicine7
进行中（未招募）
不适用
HD 17 for intermediate stage Hodgkin lymphoma: randomised treatment based on results of FDG-PET scaHodgkin Lymphoma intermediate stageMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2007-005920-34-NLVU University Medical Center1,100
进行中（未招募）
1 期
HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET - HD17Hodgkin Lymphoma intermediate stageMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2007-005920-34-DEniversity of Cologne1,100